MGCL.F Stock Overview
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Argent BioPharma Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | AU$0.26 |
52 Week High | AU$6.90 |
52 Week Low | AU$0.23 |
Beta | 0.98 |
1 Month Change | -10.18% |
3 Month Change | n/a |
1 Year Change | -95.51% |
3 Year Change | -99.44% |
5 Year Change | -99.15% |
Change since IPO | -99.36% |
Recent News & Updates
Recent updates
Shareholder Returns
MGCL.F | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -1.5% | -0.6% | 1.0% |
1Y | -95.5% | 10.6% | 21.9% |
Return vs Industry: MGCL.F underperformed the US Pharmaceuticals industry which returned 13.2% over the past year.
Return vs Market: MGCL.F underperformed the US Market which returned 24.9% over the past year.
Price Volatility
MGCL.F volatility | |
---|---|
MGCL.F Average Weekly Movement | n/a |
Pharmaceuticals Industry Average Movement | 9.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.8% |
10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MGCL.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MGCL.F's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | n/a | Roby Zomer | mgcpharma.com.au |
Argent BioPharma Limited, a drug discovery clinical-stage biopharmaceutical company, provides medicines targeting immunology and neurology worldwide. Its principal product candidates include CimetrA, which is in phase II clinical trial for the treatment of SLE Lupus, anti-inflammatory, and SARS COVID-19; and CannEpil, which is in phase I clinical trial for refractory epilepsy and cerebral palsy; and CogniCann, which is in phase I clinical trial for the symptomatic relief of Dementia and Alzheimer. In addition, the company provides Irnican for brain cancer.
Argent BioPharma Limited Fundamentals Summary
MGCL.F fundamental statistics | |
---|---|
Market cap | US$11.93m |
Earnings (TTM) | -US$11.07m |
Revenue (TTM) | US$861.66k |
13.8x
P/S Ratio-1.1x
P/E RatioIs MGCL.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
MGCL.F income statement (TTM) | |
---|---|
Revenue | AU$1.32m |
Cost of Revenue | AU$1.20m |
Gross Profit | AU$125.39k |
Other Expenses | AU$17.14m |
Earnings | -AU$17.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.38 |
Gross Margin | 9.47% |
Net Profit Margin | -1,284.89% |
Debt/Equity Ratio | 1,366.5% |
How did MGCL.F perform over the long term?
See historical performance and comparison